Atrility is advancing rhythm management with AtriAmp, an FDA-cleared device that enables continuous atrial electrogram monitoring in post-operative cardiac patients. By combining a growing database of atrial electrograms with machine learning, the company aims to help care teams identify and manage arrhythmias more accurately. Attendees will be interested in how Atrility is bringing data-driven insights and AI to one of the most challenging areas of cardiac rhythm monitoring.

Advanced Telesensors is developing Cardi/o®, a touchless, radar-based monitoring platform that continuously tracks heart rate and respiratory rate without requiring wearables or patient contact. Already deployed in nursing facilities across the country, the technology is designed to provide early warning of patient deterioration before a clinical crisis occurs. Attendees will gain insight into how remote sensing and predictive monitoring could transform proactive cardiovascular care.

Korion Health is reimagining home health monitoring with the SoundHeart Digital Stethoscope, a consumer-friendly device paired with augmented reality guidance to support high-quality data collection outside traditional care settings. The company’s broader vision is to create a comprehensive home monitoring platform that supports remote examinations and patient engagement. Attendees will be interested in its approach to expanding access to care while generating data for advanced analytics and AI.

KUχAI is developing Electra, a real-time AI platform designed to analyze intracardiac electrograms during catheter ablation procedures. Built on a foundation model trained on thousands of cases and tens of thousands of hours of recordings, the technology automates signal interpretation and provides real-time procedural insights. Attendees will be interested in how AI could streamline EP workflows, improve consistency, and support clinical decision-making in the lab.

Myochron is developing a software platform that helps clinicians personalize cardiac resynchronization therapy (CRT) and conduction system pacing using ECG-based measures of electrical synchrony. Designed to fit within existing workflows without requiring additional implantable hardware, the technology helps identify patient-specific device settings that may improve outcomes. Attendees will be interested in its potential to make heart failure therapies more precise and personalized.

OpMap is developing DEAP Mapping, an AI-powered software platform that provides real-time visualization of atrial substrate during catheter ablation for atrial fibrillation. By combining expertise in electrophysiology, software development, and biomedical engineering, the company aims to improve procedural guidance and decision-making. Attendees will be interested in how advanced mapping technologies could enhance AF ablation strategies and outcomes.

Perpetua AI is designing a leadless pacemaker concept that harvests energy from the heart’s own motion, reducing dependence on traditional batteries. The technology seeks to address one of the biggest limitations of implantable cardiac devices: finite battery life and the need for repeated interventions over time. Attendees will be interested in this novel approach to device longevity and the future of self-powered cardiac implants.

Rhythm Biotherapeutics is developing a first-in-class extracellular vesicle therapy designed to target the inflammatory and fibrotic processes that contribute to atrial fibrillation. Initially focused on preventing postoperative AF, the company’s long-term vision is to treat the underlying disease rather than simply managing arrhythmias. Attendees will be interested in the potential for biologic therapies to reshape the future of AF treatment.

SAFE4BOTH is an AI-driven maternal and cardiovascular health platform that supports continuous care from pregnancy through the postpartum period. By combining remote monitoring, early risk detection, clinician dashboards, and coordinated care pathways, the platform aims to improve outcomes for mothers and infants. Attendees will find value in its innovative approach to addressing cardiovascular risk during and after pregnancy.

Vibrant Medical is developing a wearable ultrasound neck patch designed to continuously monitor blood flow to the brain and detect strokes before clinical symptoms become apparent. The technology addresses a major gap in inpatient monitoring, particularly for patients at elevated cardiovascular and neurovascular risk. Attendees will be interested in the potential to dramatically reduce stroke detection delays and improve outcomes through continuous monitoring.